Skip to main content Accessibility help
×
Home

Dual antiplatelet treatment in TIA and high-risk ischemic CVA, a review of the POINT trial

  • Margaret Hull (a1)

Abstract

  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.

Copyright

Corresponding author

Correspondence to: Dr. Margaret Hull, 4315 St Hubert, Apt 11, Montreal, QCH2J 2W6; Email: margaret.hull@mail.mcgill.ca

References

Hide All
1.Wang, Y, Wang, Y, Zhao, X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369(1):11–9.10.1056/NEJMoa1215340
2.Johnston, SC, Amarenco, P, Albers, GW, et al. Ticagrelor versus aspirin in acute stroke and TIA. N Engl J Med 2016;375:3543.10.1056/NEJMoa1603060
3.Powers, WJ, Rabinstein, AA, Ackerson, T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49(3):e46–110.10.1161/STR.0000000000000158
4.Lin, K, Lindsay, P, Shams, T, et al. A summary of the Canadian Stroke Best Practice Recommendations, Sixth Edition (2018): updates relevant to prehospital and emergency medicine providers. CJEM 2018;20(5):685–92.10.1017/cem.2018.438
5.Grotta, JC. Antiplatelet therapy after ischemic stroke or TIA. N Engl J Med 2018;379(3):291–2.10.1056/NEJMe1806043

Keywords

Dual antiplatelet treatment in TIA and high-risk ischemic CVA, a review of the POINT trial

  • Margaret Hull (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.